Statins, percutaneous coronary intervention and myocardial infarction

Jones, Alan

doi:10.1185/03007995.2013.842547

Cited by 2 publications

(3 citation statements)

References 23 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 However, one group at high risk of cardiovascular events associated with recurrent myocardium infarction and stent thrombosis are patients who had undergone PPCI. 3…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention

Kunlamas

Areepium

Ariyachaipanich

et al. 2019

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Although high-intensity statins are recommended for atherosclerotic cardiovascular disease, evidence has shown that Asians may need lower dose statins to achieve similar effect when compared to Caucasians. Moreover, awareness of adverse effects leads physicians to initiate moderate-intensity statins. Comparative of high versus moderate-intensive statins on LDL-C among patients who had undergone primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) are less established in Thailand. We conducted a retrospective cohort study to identify pattern of statins prescribing and explored the effectiveness on lipid profiles, including LDL-C goal achievement (<70 mg/dL) in STEMI patients underwent PPCI. A total of 983 patients with STEMI who had undergone PPCI were identified during 2005-2015. At 3-month follow-up, 31.9% patients were investigated for their lipid profile. There was 26.11% of patients who received high-intensity statins. When compared to baseline, we found more LDL-C reduction (38.22% ± 26.75% vs 22.36% ± 35.05%, P < .01) in the high-intensity group. Eighty-one patients achieved the target LDL-C, the high-intensity group were able to achieve the LDL-C goal than moderate-intensity group, but did not reach statistical significance (24.1% vs 30.5%, P = .26). This study confirmed that high-intensity statins have superior for LDL-C reduction and tend to achieve LDL-C goal more than moderate-intensity statins.

show abstract

“…2 However, one group at high risk of cardiovascular events associated with recurrent myocardium infarction and stent thrombosis are patients who had undergone PPCI. 3…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, after PPCI, in addition to the long-term benefits of lipid lowering, statin therapy might also play a beneficial role. 3…”

Section: Introductionmentioning

confidence: 99%

Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention

Kunlamas

Areepium

Ariyachaipanich

et al. 2019

Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

“…Currently, drugs available for the treatment of MI include angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II receptor blockers, beta-blockers (BBs), statins, nitrates and antiplatelet agents Hara et al, 2014;Jones 2014). However, the overall success of these medicines is limited, and adverse reactions are usually conspicuous.…”

Section: Introductionmentioning

confidence: 99%

Identification of NF‐κB inhibitors in Qishenyiqi dropping pills for myocardial infarction treatment based on bioactivity‐integrated UPLC‐Q/TOF MS

Han

Zhou

Xing

et al. 2015

Biomedical Chromatography

View full text Add to dashboard Cite

Qishenyiqi dropping pills (QSYQ) are a type of standardized cardiovascular multiherb medicine for the treatment of myocardial infarction (MI). Knowledge concerning the systemic identification of nuclear factor-kappa B (NF-κB) inhibitors of QSYQ is generally lacking. Therefore, it is necessary to establish an effective method to screen the bioactive components of NF-κB inhibition. In the present study, a rat model of coronary artery ligation was used to assess the cardioprotective effects of QSYQ. The electrocardiograms, histopathology of heart tissues and serum biochemical indicators, such as brain natriuretic peptide, cardiac troponin I and inflammatory cytokines, were measured. Subsequently, ultra-performance liquid chromatography quadrupole/time-of-flight mass spectrometry (UPLC-Q/TOF MS) combined with the NF-κB luciferase reporter assay system was applied to screen the potential anti-inflammatory compounds in QSYQ. The results revealed that the administration of QSYQ could improve heart function, ameliorate neutrophil infiltration and diminish the levels of inflammatory cytokines in MI rats. Furthermore, 22 compounds were determined to be potential NF-κB inhibitors. In conclusion, NF-κB inactivation and cytokine suppression might be the main mechanisms of QSYQ for MI treatment. The method of UPLC-Q/TOF MS combined with a bioactive human cell functional evaluation system was proved to be a simple and effective strategy for screening bioactive compounds in traditional Chinese medicine prescriptions.

show abstract

Statins, percutaneous coronary intervention and myocardial infarction

Cited by 2 publications

References 23 publications

Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention

Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention

Identification of NF‐κB inhibitors in Qishenyiqi dropping pills for myocardial infarction treatment based on bioactivity‐integrated UPLC‐Q/TOF MS

Contact Info

Product

Resources

About